FAQ on Tonix Pharmaceuticals' Positive Phase 3 Data for Fibromyalgia Drug TNX-102 SL
Summary
What is TNX-102 SL and what condition does it aim to treat?
TNX-102 SL is a sublingual cyclobenzaprine formulation developed by Tonix Pharmaceuticals for the treatment of fibromyalgia, designed to bypass first-pass liver metabolism for potentially enhanced efficacy.
What were the key findings from the RESILIENT Phase 3 trial?
The trial showed statistically significant, sustained pain reduction over 14 weeks, improved sleep, and favorable tolerability, with higher nighttime cyclobenzaprine levels and lower norcyclobenzaprine accumulation compared to oral formulations.
Why is TNX-102 SL considered a significant development in fibromyalgia treatment?
TNX-102 SL could become the first new fibromyalgia therapy in 15 years, offering a novel approach to pain management and sleep improvement with its unique sublingual delivery system.
When is the FDA expected to make a decision on TNX-102 SL?
The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of Aug. 15, 2025, for its decision on TNX-102 SL.
How does TNX-102 SL differ from existing fibromyalgia treatments?
TNX-102 SL’s sublingual formulation bypasses first-pass liver metabolism, achieving higher nighttime cyclobenzaprine levels and lower norcyclobenzaprine accumulation, which may enhance long-term efficacy and tolerability compared to oral formulations.
What other developments is Tonix Pharmaceuticals working on?
Tonix is developing therapies for pain management, public health challenges, CNS disorders, immunology, rare diseases, and infectious diseases, including TNX-1300 for cocaine intoxication and TNX-1500 for organ transplant rejection and autoimmune diseases.
Where can I find more information about Tonix Pharmaceuticals and TNX-102 SL?
More information is available on Tonix Pharmaceuticals’ website at www.TonixPharma.com and in the company’s newsroom at https://ibn.fm/TNXP.
What is the significance of the Fast Track designation for TNX-102 SL?
The FDA’s Fast Track designation for TNX-102 SL underscores its potential to address an unmet need in fibromyalgia treatment, facilitating an expedited review process to bring the therapy to patients more quickly.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 108849